Data from the first blinded cohort of eight patients, two of whom received placebo and six of whom received a single dose of 6 mg of VIR-3434, showed that six of eight patients achieved a mean reduction of 1.3 log10 IU/mL in serum hepatitis B virus surface antigen (HBsAg) by day eight, the day when nadir was achieved in most patients.
Vir 治疗乙肝的 Vir 3434 单抗T- cell疫苗取得了令人震惊的效果。只用了6mg就将乙肝病毒的表面抗原下降了1.3个log。这个剂量非常低，Vir预计还要进一步提高剂量。
而且请注意，这个数据不是来自于之前RNAi的，而是Vir自家的单抗。
Vir可是打算把这个单抗和RNAi一起用于治疗乙肝病毒的。可以想象这个联合疗法的威力。
这样一来$Arrowhead制药(ARWR)$ 可就有点尴尬了啊。